Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: NPC

June 30, 2021 CD as API / Pharma applications

Recent reviews on cyclodextrins against SARS-CoV-2

Recent reviews emphasized the role of membrane lipids in the infectivity mechanism of SARS-COV-2. Cholesterol-rich parts of cell membranes serve

Continue reading

January 8, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Positive Efficacy Data in Patients with Niemann-Pick Disease Type C

Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization Cyclo

Continue reading

September 7, 2020 CD as API / Pharma applications

Potential COVID-19 therapeutics from a rare disease: utilization of lipid dysregulation to combat viral infectivity

Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and

Continue reading

March 26, 2020 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics announces positive safety profile of its drug Trappsol Cyclo

Cyclo Therapeutics, Inc., a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)

Continue reading

February 6, 2020 CD as API / CD derivatives / Pharma applications / Uncategorized

Cyclo Therapeutics Presents Clinical Trial Data on Niemann-Pick Type C Disease

Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)

Continue reading

October 25, 2019 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced

Continue reading

February 20, 2019 CD as API / CD derivatives

CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™

CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical

Continue reading

December 6, 2018 CD derivatives / Drug delivery / Events / Pharma applications

Opinion leaders of CD society getting together in Budapest

In the recent two weeks, Cyclolab had the pleasure to welcome two prominent pioneers of cyclodextrin research, Prof. Loftsson from

Continue reading

September 22, 2018 CD as API / Pharma applications

Therapeutic potential for cyclodextrin‐based macromolecular systems in NPC

A paper has just come out in Macromolecular Rapid Communications highlighting the potential benefits of cyclodextrin-based macromolecular systems as cholesterol-mopping

Continue reading

August 30, 2018 CD as API / Pharma applications

Different cyclodextrins to treat NPC

If you are following advances in the re-discovery of cyclodextrins as APIs, there is quite a race among the candidates

Continue reading

Posts navigation

1 2 Next Posts»

Recent Posts

  • Cholesterol/β-cyclodextrin complexation revisited by combined experimental and computational approaches
  • Cyclodextrin improve the composition of dairy products, an example in food industry
  • International Conference on Bioinspiration and Biobased​ Materials
  • Molecular docking assisted exploration on solubilization of poorly soluble drug remdesivir in sulfobutyl ether-beta-cyclodextrin
  • Have you ever washed your hands with HPBCD-containing soap? Check it out!

Tags

antiviral Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead History HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir SBECD Special issue Sugammadex Synthesis Trappsol wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (13)
  • Analysis (25)
  • CD as API (174)
  • CD derivatives (220)
  • Cosmetics and toilettry (15)
  • Drug delivery (338)
  • E-ducation (49)
  • Environmental (61)
  • Events (142)
  • Food (96)
  • Gene delivery (6)
  • In Hungarian (4)
  • Life sciences (8)
  • Non-pharma applications (155)
  • Other industrial use (49)
  • Pharma applications (573)
  • Supramolecular systems (18)
  • Uncategorized (32)

Top Posts

  • Cholesterol/β-cyclodextrin complexation revisited by combined experimental and computational approaches
  • Cyclodextrin improve the composition of dairy products, an example in food industry
  • Have you ever washed your hands with HPBCD-containing soap? Check it out!
  • Self-Inclusion and Dissociation of a Bridging β‑Cyclodextrin Triplet
  • Mallinckrodt gave up further development of adrabetadex (VTS-270; HPBCD)
  • GRAS status of CD derivatives
  • Regorafenib@mannose-γ-cyclodextrin channel-type nanoparticles for colorectal cancer therapy
  • SBECD partly inhibits the renal excretion of anionic drugs
  • How air fresheners work?
  • Program of International Cyclodextrin Symposium

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 417 other subscribers

 

Loading Comments...